Bolt Biotherapeutics, Inc. (BOLT): Nasdaq/NYSE listing notice — Bolt Biotherapeutics transfers to Nasdaq Capital Market to extend bid price compliance deadline to June 30, 2025

Bolt Biotherapeutics, Inc.

Transfer approved Jan 2, 2025; effective at market open Jan 6, 2025.
Company failed to regain $1 minimum bid price by original Dec 30, 2024 deadline.
Additional compliance period until June 30, 2025; must close at $1+ for 10 consecutive business days.
Bolt may effect a reverse stock split to cure the deficiency if needed.
Failure to regain compliance by June 30 could lead to delisting and a potential Nasdaq appeal.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Bolt Biotherapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

January 2, 2025, the Company received written notice from Nasdaq notifying the Company that its application to transfer the listing of its common stock to The Nasdaq Capital Market was approved. The approval is based upo

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-001159

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.